Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826612 · ClinicalTrials.gov registry record · Phase 1
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
A Phase 1 study of Huntington Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 5
- Study locations
NCT06826612 is a Phase 1 study of Huntington Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 53 participants, below the 634-participant average among 35 other Huntington Disease trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT06826612, a Phase 1 study of Huntington Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Conditions Studied
Interventions
- GENETIC SPK-10001
- OTHER Placebo Surgery Control
Study Locations (5)
Ohio
- University of Cincinnati/Cincinnati Children's Hospital - Cincinnati
- Ohio State University - Columbus
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburg - Pittsburgh
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2035-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06826612
The ClinicalTrials.gov registry entry for NCT06826612 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 634-participant average among 35 other Huntington Disease trials with a reported enrollment target (92% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which SPK-10001 is the first listed.
NCT06826612 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Pennsylvania, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06826612 about?
NCT06826612 is a clinical study titled "A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease". The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
What is the current status of trial NCT06826612?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2025-02-21. Estimated completion is 2035-01-12.
What conditions does trial NCT06826612 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT06826612?
The interventions under investigation include: SPK-10001 (GENETIC), Placebo Surgery Control (OTHER).
Who is sponsoring clinical trial NCT06826612?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06826612 being conducted?
This trial has 5 study locations across Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
COMPLETED · Phase 1
-
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
COMPLETED · Phase 1
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.